{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:46:16Z","timestamp":1782729976466,"version":"3.54.5"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00612-2","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T08:50:05Z","timestamp":1782723005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic targeting of COX-2 in head and neck cancer: Mechanistic and clinical perspectives"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0503-8580","authenticated-orcid":false,"given":"Reena","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Khaleel Midhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabir","family":"Ali Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abohassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pareshkumar","family":"N. Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunjan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Priyadarshini Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Shahid Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainb","family":"A. Taleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"612_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.hoc.2018.12.006","volume":"33","author":"F Sim","year":"2019","unstructured":"Sim F, Leidner R, Bell RB. Immunotherapy for Head and Neck Cancer. Hematol Oncol Clin North Am. 2019;33:301\u201321.","journal-title":"Hematol Oncol Clin North Am"},{"key":"612_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.12968\/ijpn.2022.28.7.333","volume":"28","author":"A Weaver","year":"2022","unstructured":"Weaver A, Smith M, Wilson S, Douglas CM, Montgomery J, Finlay F. Palliation of head and neck cancer: a review of the unique difficulties. Int J Palliat Nurs. 2022;28:333\u201341.","journal-title":"Int J Palliat Nurs"},{"key":"612_CR3","doi-asserted-by":"publisher","first-page":"110548","DOI":"10.1016\/j.nut.2019.06.028","volume":"69","author":"MB Kristensen","year":"2020","unstructured":"Kristensen MB, Isenring E, Brown B. Nutrition and swallowing therapy strategies for patients with head and neck cancer. Nutrition. 2020;69:110548.","journal-title":"Nutrition"},{"key":"612_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/jjco\/hyx151","volume":"48","author":"WT Ng","year":"2018","unstructured":"Ng WT, Wong ECY, Lee VHF, Chan JYW, Lee AWM. Head and neck cancer in Hong Kong. Jpn J Clin Oncol. 2018;48:13\u201321.","journal-title":"Jpn J Clin Oncol"},{"key":"612_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11864-017-0484-y","volume":"18","author":"SH Huang","year":"2017","unstructured":"Huang SH, O\u2019Sullivan B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Curr Treat Options Oncol. 2017;18:40.","journal-title":"Curr Treat Options Oncol"},{"key":"612_CR6","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1017\/S0022215123000695","volume":"137","author":"K Hulse","year":"2023","unstructured":"Hulse K, Li LQ, Lowit A, Maguire R, Douglas C. Digital health in head and neck cancer: a systematic review. J Laryngol Otol. 2023;137:1312\u201325.","journal-title":"J Laryngol Otol"},{"key":"612_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1053\/j.seminoncol.2019.07.002","volume":"46","author":"D Alterio","year":"2019","unstructured":"Alterio D, Marvaso G, Ferrari A, Volpe S, Orecchia R, Jereczek-Fossa BA. Modern radiotherapy for head and neck cancer. Semin Oncol. 2019;46:233\u201345.","journal-title":"Semin Oncol"},{"key":"612_CR8","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41415-022-5166-x","volume":"233","author":"M Gormley","year":"2022","unstructured":"Gormley M, Creaney G, Schache A, Ingarfield K, Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. 2022;233:780\u20136.","journal-title":"Br Dent J"},{"key":"612_CR9","doi-asserted-by":"publisher","first-page":"104781","DOI":"10.1016\/j.critrevonc.2025.104781","volume":"213","author":"I Mascagni","year":"2025","unstructured":"Mascagni I, Bossi P. The loop between inflammation and late systemic toxicity in head and neck cancer survivors. Crit Rev Oncol Hematol. 2025;213:104781.","journal-title":"Crit Rev Oncol Hematol"},{"key":"612_CR10","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1007\/s12325-022-02074-9","volume":"39","author":"AA M\u00e4kitie","year":"2022","unstructured":"M\u00e4kitie AA, Alabi RO, Orell H, Youssef O, Almangush A, Homma A, et al. Managing Cachexia in Head and Neck Cancer: a Systematic Scoping Review. Adv Ther. 2022;39:1502\u201323.","journal-title":"Adv Ther"},{"key":"612_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1053\/j.semnuclmed.2020.07.008","volume":"51","author":"C Marcus","year":"2021","unstructured":"Marcus C, Subramaniam RM. Role of Non-FDG-PET\/CT in Head and Neck Cancer. Semin Nucl Med. 2021;51:68\u201378.","journal-title":"Semin Nucl Med"},{"key":"612_CR12","doi-asserted-by":"publisher","first-page":"116221","DOI":"10.1016\/j.bcp.2024.116221","volume":"224","author":"N Thi Thanh Nguyen","year":"2024","unstructured":"Thi Thanh Nguyen N, Yoon Lee S. Celecoxib and sulindac sulfide elicit anticancer effects on PIK3CA-mutated head and neck cancer cells through endoplasmic reticulum stress, reactive oxygen species, and mitochondrial dysfunction. Biochem Pharmacol. 2024;224:116221.","journal-title":"Biochem Pharmacol"},{"key":"612_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1476-4598-10-12","volume":"10","author":"R Wilken","year":"2011","unstructured":"Wilken R, Veena MS, Wang MB, Srivatsan ES, Curcumin. A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer. 2011;10:12.","journal-title":"Mol Cancer"},{"key":"612_CR14","first-page":"803","volume":"22","author":"JC Wilson","year":"2011","unstructured":"Wilson JC, Anderson LA, Murray LJ, Hughes CM. Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and neck cancer: a systematic review. Cancer Causes Control. 2011;22:803\u201310.","journal-title":"Cancer Causes Control"},{"key":"612_CR15","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.ejso.2005.01.006","volume":"31","author":"C M\u00f6bius","year":"2005","unstructured":"M\u00f6bius C, Stein HJ, Spiess C, Becker I, Feith M, Theisen J, et al. COX2 expression, angiogenesis, proliferation and survival in Barrett\u2019s cancer. Eur J Surg Oncol. 2005;31:755\u20139.","journal-title":"Eur J Surg Oncol"},{"key":"612_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/ijms22041912","volume":"22","author":"B Peltanova","year":"2021","unstructured":"Peltanova B, Liskova M, Gumulec J, Raudenska M, Polanska HH, Vaculovic T, et al. Sensitivity to Cisplatin in Head and Neck Cancer Cells Is Significantly Affected by Patient-Derived Cancer-Associated Fibroblasts. Int J Mol Sci. 2021;22:31\u201340.","journal-title":"Int J Mol Sci"},{"key":"612_CR17","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/hed.10108","volume":"24","author":"DT Lin","year":"2002","unstructured":"Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck. 2002;24:792\u20139.","journal-title":"Head Neck"},{"key":"612_CR18","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1016\/j.oraloncology.2009.03.016","volume":"45","author":"RA Mendes","year":"2009","unstructured":"Mendes RA, Carvalho JF, Waal I. An overview on the expression of cyclooxygenase-2 in tumors of the head and neck. Oral Oncol. 2009;45:e124\u20138.","journal-title":"Oral Oncol"},{"key":"612_CR19","first-page":"41","volume":"16","author":"S Lang","year":"2003","unstructured":"Lang S, Zeidler R. Immune restoration in head and neck cancer patients via cyclooxygenase inhibition: an update. Int J Immunopathol Pharmacol. 2003;16:41\u20138.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"612_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3892\/ol.2021.12794","volume":"22","author":"S Saito","year":"2021","unstructured":"Saito S, Ozawa H, Imanishi Y, Sekimizu M, Watanabe Y, Ito F, et al. Cyclooxygenase-2 expression is associated with chemoresistance through cancer stemness property in hypopharyngeal carcinoma. Oncol Lett. 2021;22:533.","journal-title":"Oncol Lett"},{"key":"612_CR21","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1158\/1940-6207.CAPR-24-0093","volume":"17","author":"S Han","year":"2024","unstructured":"Han S, Bommireddy R, Kim P, Selvaraj P, Shin DM. Chemoprevention of Head and Neck Cancer: A Review of Current Approaches and Future Perspectives. Cancer Prev Res (Phila). 2024;17:443\u201355.","journal-title":"Cancer Prev Res (Phila)"},{"key":"612_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10059-010-0026-y","volume":"29","author":"YY Kim","year":"2010","unstructured":"Kim YY, Lee EJ, Kim YK, Kim SM, Park JY, Myoung H, et al. Anti-cancer effects of celecoxib in head and neck carcinoma. Mol Cells. 2010;29:185\u201394.","journal-title":"Mol Cells"},{"key":"612_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2174\/0113892029278082240118053857","volume":"25","author":"A Xing","year":"2024","unstructured":"Xing A, Lv D, Wu C, Zhou K, Zhao T, Zhao L, et al. Tertiary Lymphoid Structures Gene Signature Predicts Prognosis and Immune Infiltration Analysis in Head and Neck Squamous Cell Carcinoma. Curr Genomics. 2024;25:88\u2013104.","journal-title":"Curr Genomics"},{"key":"612_CR24","doi-asserted-by":"publisher","first-page":"e18761429317532","DOI":"10.2174\/0118761429317532241017051135","volume":"17","author":"YW Wang","year":"2024","unstructured":"Wang YW, Huang BR, Lu DY, Chen JW, Charoensaensuk V, Yang LY, et al. Fenofibrate Inhibits LPS and Zymosan-induced Inflammatory Responses through Sonic Hedgehog in IMG Cells. Curr Mol Pharmacol. 2024;17:e18761429317532.","journal-title":"Curr Mol Pharmacol"},{"key":"612_CR25","doi-asserted-by":"crossref","unstructured":"Sundararajan K, Gurusamy V, Venkatesh S, Saraswathi M. COX-2 Expression as a Prognostic Inflammatory Marker in Head and Neck Squamous Cell Carcinoma: A Cross-sectional Study. 2023;12;09\u2013013.","DOI":"10.7860\/NJLM\/2023\/63349.2762"},{"key":"612_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.31557\/APJCP.2024.25.3.757","volume":"25","author":"FF Biasin","year":"2024","unstructured":"Biasin FF, Franco AM, Louzeiro GC, Cherubini K, Salum FG. Association of COX-2, TNF-\u03b1, TLR4, and IKK\u03b1 With Survival of Patients With Oral Squamous Cell Carcinomas: A Systematic Review. Asian Pac J Cancer Prevention: APJCP. 2024;25:757.","journal-title":"Asian Pac J Cancer Prevention: APJCP"},{"key":"612_CR27","first-page":"e18761429385248","volume":"17","author":"A Alqudah","year":"2024","unstructured":"Alqudah A, Barakat M, Alzaghari LF, Qnais E, Gammoh O, Alqudah M, et al. Mechanistic Insights into Isorhamnetin: Targeting MAPK and NF-\u03baB Pathways to Mitigate LPS-Induced Inflammation. Curr Mol Pharmacol. 2024;17:e18761429385248.","journal-title":"Curr Mol Pharmacol"},{"key":"612_CR28","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.bcp.2005.05.004","volume":"70","author":"K Kashfi","year":"2005","unstructured":"Kashfi K, Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol. 2005;70:969\u201386.","journal-title":"Biochem Pharmacol"},{"key":"612_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13046-018-0926-9","volume":"37","author":"Y Peng","year":"2018","unstructured":"Peng Y, Wang Y, Tang N, Sun D, Lan Y, Yu Z, et al. Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J Exp Clin Cancer Res. 2018;37:248.","journal-title":"J Exp Clin Cancer Res"},{"key":"612_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1023\/A:1025731204719","volume":"8","author":"LR Howe","year":"2003","unstructured":"Howe LR, Dannenberg AJ. COX-2 inhibitors for the prevention of breast cancer. J Mammary Gland Biol Neoplasia. 2003;8:31\u201343.","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"612_CR31","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.1002\/jcp.27411","volume":"234","author":"N Hashemi Goradel","year":"2019","unstructured":"Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase-2 in cancer: A review. J Cell Physiol. 2019;234:5683\u201399.","journal-title":"J Cell Physiol"},{"key":"612_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/(SICI)1097-4644(2000)77:34+<97::AID-JCB16>3.0.CO;2-Z","volume":"34","author":"DB Fournier","year":"2000","unstructured":"Fournier DB, Gordon GB. COX-2 and colon cancer: potential targets for chemoprevention. J Cell Biochem Suppl. 2000;34:97\u2013102.","journal-title":"J Cell Biochem Suppl"},{"key":"612_CR33","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/bega.2001.0237","volume":"15","author":"KE Giercksky","year":"2001","unstructured":"Giercksky KE. COX-2 inhibition and prevention of cancer. Best Pract Res Clin Gastroenterol. 2001;15:821\u201333.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"612_CR34","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1042\/BST0360543","volume":"36","author":"KA Harper","year":"2008","unstructured":"Harper KA, Tyson-Capper AJ. Complexity of COX-2 gene regulation. Biochem Soc Trans. 2008;36:543\u20135.","journal-title":"Biochem Soc Trans"},{"key":"612_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000071363","volume":"37","author":"DA Dixon","year":"2003","unstructured":"Dixon DA. Regulation of COX-2 expression in human cancers. Prog Exp Tumor Res. 2003;37:52\u201371.","journal-title":"Prog Exp Tumor Res"},{"key":"612_CR36","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/sj.bjp.0704365","volume":"134","author":"Y Bakhle","year":"2001","unstructured":"Bakhle Y. COX-2 and cancer: a new approach to an old problem. Br J Pharmacol. 2001;134:1137.","journal-title":"Br J Pharmacol"},{"key":"612_CR37","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.gene.2012.12.110","volume":"518","author":"S Dasdemir","year":"2013","unstructured":"Dasdemir S, Cetinkaya Y, Gencer M, Ozkok E, Aydin M, Cakmakoglu B. Cox-2 gene variants in migraine. Gene. 2013;518:292\u20135.","journal-title":"Gene"},{"key":"612_CR38","doi-asserted-by":"publisher","first-page":"635","DOI":"10.2174\/1381612043453171","volume":"10","author":"DA Dixon","year":"2004","unstructured":"Dixon DA. Dysregulated post-transcriptional control of COX-2 gene expression in cancer. Curr Pharm Design. 2004;10:635\u201346.","journal-title":"Curr Pharm Design"},{"key":"612_CR39","doi-asserted-by":"crossref","unstructured":"Herschman HR. Regulation and function of prostaglandin synthase 2\/cyclooxygenase II. eicosanoids. 2004:10;43\u201352.","DOI":"10.1002\/0470020628.ch4"},{"key":"612_CR40","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1073\/pnas.88.7.2692","volume":"88","author":"X Xie","year":"1991","unstructured":"Xie X, Chipman JG, Robertson DL, Erikson R, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci. 1991;88:2692\u20136.","journal-title":"Proc Natl Acad Sci"},{"key":"612_CR41","first-page":"e28579","volume":"14","author":"V Ganduri","year":"2022","unstructured":"Ganduri V, Rajasekaran K, Duraiyarasan S, Adefuye MA, Manjunatha N. Colorectal Carcinoma, Cyclooxygenases, and COX Inhibitors. Cureus. 2022;14:e28579.","journal-title":"Cureus"},{"key":"612_CR42","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10555-018-9752-y","volume":"37","author":"D Tong","year":"2018","unstructured":"Tong D, Liu Q, Wang LA, Xie Q, Pang J, Huang Y, et al. The roles of the COX2\/PGE2\/EP axis in therapeutic resistance. Cancer Metastasis Rev. 2018;37:355\u201368.","journal-title":"Cancer Metastasis Rev"},{"key":"612_CR43","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s00404-020-05559-6","volume":"301","author":"Y Ye","year":"2020","unstructured":"Ye Y, Wang X, Jeschke U. von Sch\u00f6nfeldt V. COX-2-PGE(2)-EPs in gynecological cancers. Arch Gynecol Obstet. 2020;301:1365\u201375.","journal-title":"Arch Gynecol Obstet"},{"key":"612_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2004.06.014","volume":"215","author":"S Zha","year":"2004","unstructured":"Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett. 2004;215:1\u201320.","journal-title":"Cancer Lett"},{"key":"612_CR45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4103\/sjg.SJG_46_18","volume":"24","author":"FF Zhou","year":"2018","unstructured":"Zhou FF, Huang R, Jiang J, Zeng XH, Zou SQ. Correlated non-nuclear COX2 and low HER2 expression confers a good prognosis in colorectal cancer. Saudi J Gastroenterol. 2018;24:301\u20136.","journal-title":"Saudi J Gastroenterol"},{"key":"612_CR46","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.0959-9673.2005.00447.x","volume":"86","author":"GR Thomas","year":"2005","unstructured":"Thomas GR, Nadiminti H, Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol. 2005;86:347\u201363.","journal-title":"Int J Exp Pathol"},{"key":"612_CR47","doi-asserted-by":"publisher","first-page":"47265","DOI":"10.18632\/oncotarget.10059","volume":"7","author":"B Yang","year":"2016","unstructured":"Yang B, Jia L, Guo Q, Ren H, Hu Y, Xie T. Clinicopathological and prognostic significance of cyclooxygenase-2 expression in head and neck cancer: A meta-analysis. Oncotarget. 2016;7:47265\u201377.","journal-title":"Oncotarget"},{"key":"612_CR48","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1158\/1940-6207.CAPR-13-0215","volume":"7","author":"NF Saba","year":"2014","unstructured":"Saba NF, Hurwitz SJ, Kono SA, Yang CS, Zhao Y, Chen Z, et al. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila). 2014;7:283\u201391.","journal-title":"Cancer Prev Res (Phila)"},{"key":"612_CR49","doi-asserted-by":"publisher","first-page":"25267","DOI":"10.31083\/FBL25267","volume":"30","author":"PG Meliante","year":"2025","unstructured":"Meliante PG, Pizzolante S, Perna L, Filippi C, Bandiera G, Barbato C, et al. Molecular Markers of Occult Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients. Front Biosci (Landmark Ed). 2025;30:25267.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"612_CR50","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1080\/15384047.2015.1071741","volume":"21","author":"A Santoro","year":"2020","unstructured":"Santoro A, Bufo P, Russo G, Cagiano S, Papagerakis S, Bucci P, et al. Expression and clinical implication of cyclooxygenase-2 and E-cadherin in oral squamous cell carcinomas. Cancer Biol Ther. 2020;21:667\u201374.","journal-title":"Cancer Biol Ther"},{"key":"612_CR51","doi-asserted-by":"crossref","unstructured":"Chiari F, Filippini DM, Fermi M, Presutti L, Caporale CD, Bertino G et al. Survival behavior of patients treated with curative and palliative electrochemotherapy for oral and oropharyngeal cancer: a systematic review. Eur Arch Otorhinolaryngol. 2025: 251\u201316.","DOI":"10.1007\/s00405-025-09843-6"},{"key":"612_CR52","doi-asserted-by":"crossref","unstructured":"Fermi M, Guarino P, Chiari F, Serafini E, Filippini DM, Ferrulli G et al. Survival rates in head and neck cutaneous squamous cell carcinoma with nodal metastases: a multicenter study. Eur Arch Otorhinolaryngol. 2026: 111\u201311.","DOI":"10.1007\/s00405-025-09887-8"},{"key":"612_CR53","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jobcr.2023.07.002","volume":"13","author":"MV Kamal","year":"2023","unstructured":"Kamal MV, Damerla RR, Dikhit PS, Kumar NA. Prostaglandin-endoperoxide synthase 2 (PTGS2) gene expression and its association with genes regulating the VEGF signaling pathway in head and neck squamous cell carcinoma. J Oral Biol Craniofac Res. 2023;13:567\u201374.","journal-title":"J Oral Biol Craniofac Res"},{"key":"612_CR54","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3892\/ijo.2016.3537","volume":"49","author":"FS Yu","year":"2016","unstructured":"Yu FS, Lin ML, Hsu SC, Yu CC, Huang YP, Kuo YH, et al. 4-Hydroxybutenolide impairs cell migration, and invasion of human oral cancer SCC-4 cells via the inhibition of NF-\u03baB and MAPK signaling pathways. Int J Oncol. 2016;49:579\u201388.","journal-title":"Int J Oncol"},{"key":"612_CR55","doi-asserted-by":"publisher","first-page":"66","DOI":"10.7150\/jca.5112","volume":"4","author":"S Koontongkaew","year":"2013","unstructured":"Koontongkaew S. The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer. 2013;4:66\u201383.","journal-title":"J Cancer"},{"key":"612_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4161\/cbt.6.1.3470","volume":"6","author":"JM Bock","year":"2007","unstructured":"Bock JM, Menon SG, Goswami PC, Sinclair LL, Bedford NS, Jackson RE, et al. Differential activity of sulindac metabolites against squamous cell carcinoma of the head and neck is mediated by p21waf1\/cip1 induction and cell cycle inhibition. Cancer Biol Ther. 2007;6:30\u20139.","journal-title":"Cancer Biol Ther"},{"key":"612_CR57","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/path.4453","volume":"235","author":"M Camacho","year":"2015","unstructured":"Camacho M, Pi\u00f1eiro Z, Alcolea S, Garc\u00eda J, Balart J, Terra X, et al. Prostacyclin-synthase expression in head and neck carcinoma patients and its prognostic value in the response to radiotherapy. J Pathol. 2015;235:125\u201335.","journal-title":"J Pathol"},{"key":"612_CR58","first-page":"2089","volume":"22","author":"DW Lee","year":"2002","unstructured":"Lee DW, Sung MW, Park SW, Seong WJ, Roh JL, Park B, et al. Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs. Anticancer Res. 2002;22:2089\u201396.","journal-title":"Anticancer Res"},{"key":"612_CR59","first-page":"991","volume":"59","author":"G Chan","year":"1999","unstructured":"Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59:991\u20134.","journal-title":"Cancer Res"},{"key":"612_CR60","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10006-009-0181-5","volume":"14","author":"M Scheer","year":"2010","unstructured":"Scheer M, Drebber U, Breuhahn K, M\u00f6ckel C, Reuther T, Kern M, et al. Expression of cyclooxygenase-2 (COX-2) in an advanced metastasized hypopharyngeal carcinoma and cultured tumor cells. Oral maxillofacial Surg. 2010;14:53\u20137.","journal-title":"Oral maxillofacial Surg"},{"key":"612_CR61","doi-asserted-by":"publisher","first-page":"S769","DOI":"10.4103\/jpbs.jpbs_135_22","volume":"14","author":"P Aparnadevi","year":"2022","unstructured":"Aparnadevi P, Nirmal RM, Veeravarmal V, Nandini DB, Kalyani C, Singh DN, et al. Cyclooxygenase-2 (COX-2) expression in oral submucous fibrosis and oral squamous cell carcinoma: an immunohistochemical study. J Pharm Bioallied Sci. 2022;14:S769\u201373.","journal-title":"J Pharm Bioallied Sci"},{"key":"612_CR62","first-page":"1888","volume":"92","author":"CAO Nathan","year":"2001","unstructured":"Nathan CAO, Leskov IL, Lin M, Abreo FW, Shi R, Hartman GH, et al. COX-2 expression in dysplasia of the head and neck: Correlation with eIF4E. Cancer. Interdisciplinary Int J Am Cancer Soc. 2001;92:1888\u201395.","journal-title":"Interdisciplinary Int J Am Cancer Soc"},{"key":"612_CR63","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/sj.bjc.6600865","volume":"88","author":"K Maaser","year":"2003","unstructured":"Maaser K, D\u00e4ubler P, Barthel B, Heine B, Von Lampe B, Stein H, et al. Oesophageal squamous cell neoplasia in head and neck cancer patients: upregulation of COX-2 during carcinogenesis. Br J Cancer. 2003;88:1217\u201322.","journal-title":"Br J Cancer"},{"key":"612_CR64","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.neo.7900127","volume":"3","author":"O Gallo","year":"2001","unstructured":"Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddit V, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia. 2001;3:53\u201361.","journal-title":"Neoplasia"},{"key":"612_CR65","first-page":"1073","volume":"10","author":"S-C Lim","year":"2003","unstructured":"Lim S-C, Park S-Y, Do N-Y. Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma. Oncol Rep. 2003;10:1073\u20139.","journal-title":"Oncol Rep"},{"key":"612_CR66","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jobcr.2023.07.002","volume":"13","author":"MV Kamal","year":"2023","unstructured":"Kamal MV, Damerla RR, Dikhit PS, Kumar NA. Prostaglandin-endoperoxide synthase 2 (PTGS2) gene expression and its association with genes regulating the VEGF signaling pathway in head and neck squamous cell carcinoma. J Oral Biology Craniofac Res. 2023;13:567\u201374.","journal-title":"J Oral Biology Craniofac Res"},{"key":"612_CR67","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/hed.21058","volume":"31","author":"WH Peters","year":"2009","unstructured":"Peters WH, Lacko M, Te Morsche RH, Voogd AC, Oude Ophuis MB, Manni JJ. COX-2 polymorphisms and the risk for head and neck cancer in white patients. Head Neck: J Sci Specialties Head Neck. 2009;31:938\u201343.","journal-title":"Head Neck: J Sci Specialties Head Neck"},{"key":"612_CR68","doi-asserted-by":"publisher","first-page":"9246","DOI":"10.3390\/ijms21239246","volume":"21","author":"E Frejborg","year":"2020","unstructured":"Frejborg E, Salo T, Salem A. Role of cyclooxygenase-2 in head and neck tumorigenesis. Int J Mol Sci. 2020;21:9246.","journal-title":"Int J Mol Sci"},{"key":"612_CR69","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/1940-6207.CAPR-09-0077","volume":"2","author":"NF Saba","year":"2009","unstructured":"Saba NF, Choi M, Muller S, Shin HJC, Tighiouart M, Papadimitrakopoulou VA, et al. Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res. 2009;2:823\u20139.","journal-title":"Cancer Prev Res"},{"key":"612_CR70","first-page":"203","volume":"9","author":"HJ Cao","year":"2009","unstructured":"Cao HJ, Lin H-Y, Luidens MK, Keating T, Grandis JR, Davis FB. COX-2, cell proliferation and PMA in head-and-neck cancer cells. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Immunology. Endocr Metabolic Agents). 2009;9:203\u201318.","journal-title":"Endocr Metabolic Agents)"},{"key":"612_CR71","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/modpathol.3800244","volume":"18","author":"PA Kyzas","year":"2005","unstructured":"Kyzas PA, Stefanou D, Agnantis NJ. COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma. Mod Pathol. 2005;18:153\u201360.","journal-title":"Mod Pathol"},{"key":"612_CR72","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1053\/hupa.2002.125376","volume":"33","author":"O Gallo","year":"2002","unstructured":"Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol. 2002;33:708\u201314.","journal-title":"Hum Pathol"},{"key":"612_CR73","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1756-9966-33-40","volume":"33","author":"R Fujii","year":"2014","unstructured":"Fujii R, Imanishi Y, Shibata K, Sakai N, Sakamoto K, Shigetomi S, et al. Restoration of E-cadherin expression by selective Cox-2 inhibition and the clinical relevance of the epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. J Experimental Clin Cancer Res. 2014;33:40.","journal-title":"J Experimental Clin Cancer Res"},{"key":"612_CR74","first-page":"1096","volume":"12","author":"Y Watanabe","year":"2020","unstructured":"Watanabe Y, Imanishi Y, Ozawa H, Sakamoto K, Fujii R, Shigetomi S, et al. Selective EP2 and Cox-2 inhibition suppresses cell migration by reversing epithelial-to-mesenchymal transition and Cox-2 overexpression and E-cadherin downregulation are implicated in neck metastasis of hypopharyngeal cancer. Am J translational Res. 2020;12:1096.","journal-title":"Am J translational Res"},{"key":"612_CR75","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1111\/cas.14400","volume":"111","author":"KH Chiang","year":"2020","unstructured":"Chiang KH, Shieh JM, Shen CJ, Chang TW, Wu PT, Hsu JY, et al. Epidermal growth factor-induced COX\u20102 regulates metastasis of head and neck squamous cell carcinoma through upregulation of angiopoietin\u2010like 4. Cancer Sci. 2020;111:2004\u201315.","journal-title":"Cancer Sci"},{"key":"612_CR76","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1158\/1535-7163.MCT-04-0251","volume":"4","author":"MS Choe","year":"2005","unstructured":"Choe MS, Zhang X, Shin HJC, Shin DM, Chen Z. Interaction between epidermal growth factor receptor\u2013and cyclooxygenase 2\u2013mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther. 2005;4:1448\u201355.","journal-title":"Mol Cancer Ther"},{"key":"612_CR77","doi-asserted-by":"publisher","first-page":"5930","DOI":"10.1158\/1078-0432.CCR-03-0677","volume":"10","author":"Z Chen","year":"2004","unstructured":"Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004;10:5930\u20139.","journal-title":"Clin Cancer Res"},{"key":"612_CR78","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ijc.11498","volume":"107","author":"SW Park","year":"2003","unstructured":"Park SW, Lee SG, Song SH, Heo DS, Park BJ, Lee DW, et al. The effect of nitric oxide on cyclooxygenase-2 (COX\u20102) overexpression in head and neck cancer cell lines. Int J Cancer. 2003;107:729\u201338.","journal-title":"Int J Cancer"},{"key":"612_CR79","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1097\/SCS.0b013e31828f2491","volume":"24","author":"F Celenk","year":"2013","unstructured":"Celenk F, Bayramoglu I, Yilmaz A, Menevse A, Bayazit Y. Expression of cyclooxygenase-2, 12-lipoxygenase, and inducible nitric oxide synthase in head and neck squamous cell carcinoma. J Craniofac Surg. 2013;24:1114\u20137.","journal-title":"J Craniofac Surg"},{"key":"612_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13402-011-0051-7","volume":"35","author":"S-W Park","year":"2012","unstructured":"Park S-W, Heo D-S, Sung M-W. The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells. Cell Oncol. 2012;35:1\u20138.","journal-title":"Cell Oncol"},{"key":"612_CR81","doi-asserted-by":"publisher","first-page":"847","DOI":"10.4161\/cbt.3.9.1037","volume":"3","author":"CP Schroeder","year":"2004","unstructured":"Schroeder CP, Yang P, Newman RA, Lotan R. Eicosanoid metabolism in squamous cell carcinoma cell lines derived from primary and metastatic head and neck cancer and its modulation by celecoxib. Cancer Biol Ther. 2004;3:847\u201352.","journal-title":"Cancer Biol Ther"},{"key":"612_CR82","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/CAD.0b013e32834279f1","volume":"22","author":"S-W Park","year":"2011","unstructured":"Park S-W, Kim H-S, Choi M-S, Kim J-E, Jeong W-J, Heo D-S, et al. The influence of cyclooxygenase-1 expression on the efficacy of cyclooxygenase-2 inhibition in head and neck squamous cell carcinoma cell lines. Anticancer Drugs. 2011;22:416\u201323.","journal-title":"Anticancer Drugs"},{"key":"612_CR83","first-page":"665","volume":"23","author":"S Hashitani","year":"2003","unstructured":"Hashitani S, Urade M, Nishimura N, Maeda T, Takaoka K, Noguchi K, et al. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int J Oncol. 2003;23:665\u201372.","journal-title":"Int J Oncol"},{"key":"612_CR84","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10059-010-0026-y","volume":"29","author":"Y-Y Kim","year":"2010","unstructured":"Kim Y-Y, Lee E-J, Kim Y-K, Kim S-M, Park J-Y, Myoung H, et al. Anti-cancer effects of celecoxib in head and neck carcinoma. Mol Cells. 2010;29:185\u201394.","journal-title":"Mol Cells"},{"key":"612_CR85","doi-asserted-by":"publisher","first-page":"116221","DOI":"10.1016\/j.bcp.2024.116221","volume":"224","author":"NTT Nguyen","year":"2024","unstructured":"Nguyen NTT, Lee SY. Celecoxib and sulindac sulfide elicit anticancer effects on PIK3CA-mutated head and neck cancer cells through endoplasmic reticulum stress, reactive oxygen species, and mitochondrial dysfunction. Biochem Pharmacol. 2024;224:116221.","journal-title":"Biochem Pharmacol"},{"key":"612_CR86","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00066-009-1929-4","volume":"185","author":"C Czembirek","year":"2009","unstructured":"Czembirek C, Eder-Czembirek C, Erovic BM, Turhani D, Spittler A, Selzer E, et al. The cyclooxygenase-2 inhibitor nimesulide, a nonsteroidal analgesic, decreases the effect of radiation therapy in head-and-neck cancer cells. Strahlenther Onkol. 2009;185:310\u20137.","journal-title":"Strahlenther Onkol"},{"key":"612_CR87","first-page":"1523","volume":"14","author":"C Czembirek","year":"2005","unstructured":"Czembirek C, Eder-Czembirek C, Erovic BM, Turhani D, Selzer E, Thurnher D. Inhibition of cytotoxicity of cisplatin by cyclooxygenase-2 inhibitor nimesulide in head and neck cancer cell lines. Oncol Rep. 2005;14:1523\u20136.","journal-title":"Oncol Rep"},{"key":"612_CR88","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2174\/156800909790192437","volume":"9","author":"J Kao","year":"2009","unstructured":"Kao J, Sikora A, Fu S. Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma. Curr Cancer Drug Targets. 2009;9:931\u20137.","journal-title":"Curr Cancer Drug Targets"},{"key":"612_CR89","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1158\/1078-0432.CCR-12-3149","volume":"19","author":"DM Shin","year":"2013","unstructured":"Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Amin AR, et al. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res. 2013;19:1244\u201356.","journal-title":"Clin Cancer Res"},{"key":"612_CR90","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canlet.2004.03.043","volume":"211","author":"F Ye","year":"2004","unstructured":"Ye F, Wu J, Dunn T, Yi J, Tong X, Zhang D. Inhibition of cyclooxygenase-2 activity in head and neck cancer cells by genistein. Cancer Lett. 2004;211:39\u201346.","journal-title":"Cancer Lett"},{"key":"612_CR91","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1002\/jcb.21772","volume":"104","author":"HY Lin","year":"2008","unstructured":"Lin HY, Sun M, Tang HY, Simone TM, Wu YH, Grandis JR, et al. Resveratrol causes COX-2\u2010and p53\u2010dependent apoptosis in head and neck squamous cell cancer cells. J Cell Biochem. 2008;104:2131\u201342.","journal-title":"J Cell Biochem"},{"key":"612_CR92","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1002\/ijc.24160","volume":"124","author":"Y Hao","year":"2009","unstructured":"Hao Y, Xie T, Korotcov A, Zhou Y, Pang X, Shan L, et al. Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivovia cyclooxygenase-2 and apoptotic pathways. Int J Cancer. 2009;124:2200\u20139.","journal-title":"Int J Cancer"},{"key":"612_CR93","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/CAD.0b013e32833dada8","volume":"21","author":"S-W Park","year":"2010","unstructured":"Park S-W, Kim H-S, Hah J-W, Jeong W-J, Kim K-H, Sung M-W. Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines. Anticancer Drugs. 2010;21:823\u201330.","journal-title":"Anticancer Drugs"},{"key":"612_CR94","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/jop.12081","volume":"42","author":"AC Abrah\u00e3o","year":"2013","unstructured":"Abrah\u00e3o AC, Giudice FS, Sperandio FF, Pinto Junior DS. Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma. J oral Pathol Med. 2013;42:793\u20138.","journal-title":"J oral Pathol Med"},{"key":"612_CR95","first-page":"01","volume":"10","author":"D Li","year":"2025","unstructured":"Li D, Guo S, Wang K, Liu Z, Yu T, Zhang Y. The COX-2 Inhibitor Celecoxib Sensitizes Nasopharyngeal Carcinoma Cells to Ferroptosis. Curr Cancer Drug Targets. 2025;10:01\u20139.","journal-title":"Curr Cancer Drug Targets"},{"key":"612_CR96","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ijrobp.2005.06.007","volume":"63","author":"U Raju","year":"2005","unstructured":"Raju U, Ariga H, Dittmann K, Nakata E, Ang KK, Milas L. Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. Int J Radiation Oncology* Biology* Phys. 2005;63:520\u20138.","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"key":"612_CR97","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0360-3016(03)01577-3","volume":"57","author":"N Amirghahari","year":"2003","unstructured":"Amirghahari N, Harrison L, Smith M, Rong X, Naumann I, Ampil F, et al. NS 398 radiosensitizes an HNSCC cell line by possibly inhibiting radiation-induced expression of COX-2. Int J Radiation Oncology* Biology* Phys. 2003;57:1405\u201312.","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"key":"612_CR98","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.oraloncology.2014.08.001","volume":"50","author":"RV Lalla","year":"2014","unstructured":"Lalla RV, Choquette LE, Curley KF, Dowsett RJ, Feinn RS, Hegde UP, et al. Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol. 2014;50:1098\u2013103.","journal-title":"Oral Oncol"},{"key":"612_CR99","doi-asserted-by":"publisher","first-page":"e103653","DOI":"10.5812\/ijcm.103653","volume":"14","author":"M Aghili","year":"2021","unstructured":"Aghili M, Ghalehtaki R, Rayzan E, Farzin M, Mojahed MM, Izadi S, et al. The efficacy of celecoxib during chemoradiation in locally advanced head and neck carcinoma; a phase 2 randomized placebo control clinical trial. Int J Cancer Manag. 2021;14:e103653.","journal-title":"Int J Cancer Manag"},{"key":"612_CR100","doi-asserted-by":"publisher","first-page":"253","DOI":"10.15407\/exp-oncology.2024.03.253","volume":"46","author":"N Mitryayeva","year":"2024","unstructured":"Mitryayeva N, Grebinyk L, Artiukh S, Bilozor N, Starenkiy V. Influence of conformal radiotherapy in combination with radiomodifiers on the content of VEGF, COX-2, and PGE-2 in blood serum of patients with head and neck squamous cell carcinoma. Exp Oncol. 2024;46:253\u20139.","journal-title":"Exp Oncol"},{"key":"612_CR101","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s00262-007-0312-5","volume":"56","author":"S Lang","year":"2007","unstructured":"Lang S, Tiwari S, Andratschke M, Loehr I, Lauffer L, Bergmann C, et al. Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition. Cancer Immunol Immunother. 2007;56:1645\u201352.","journal-title":"Cancer Immunol Immunother"},{"key":"612_CR102","first-page":"e1915","volume":"7","author":"JQ Trinh","year":"2024","unstructured":"Trinh JQ, Acosta C, Easwar A, Galamaga R, Tan A. Durable and dramatic response to checkpoint inhibition combined with COX-2 inhibitor celecoxib in a patient with p16\u2009+\u2009metastatic sinonasal undifferentiated carcinoma: A case study. Cancer Rep. 2024;7:e1915.","journal-title":"Cancer Rep"},{"key":"612_CR103","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1749-6632.1999.tb08724.x","volume":"889","author":"JR Mestre","year":"1999","unstructured":"Mestre JR, Chan G, Zhang F, Yang EK, Sacks PG, Boyle JO, et al. Inhibition of cyclooxygenase-2 expression: an approach to preventing head and neck cancer. Ann N Y Acad Sci. 1999;889:62\u201371.","journal-title":"Ann N Y Acad Sci"},{"key":"612_CR104","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1158\/1078-0432.CCR-12-3149","volume":"19","author":"DM Shin","year":"2013","unstructured":"Shin DM, Zhang H, Saba NF, Chen AY, Nannapaneni S, Amin AR, et al. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res. 2013;19:1244\u201356.","journal-title":"Clin Cancer Res"},{"key":"612_CR105","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1002\/hed.28178","volume":"47","author":"P Kim","year":"2025","unstructured":"Kim P, Saba NF, McCook-Veal A, Liu Y, Klein AM, Beitler JJ, et al. Prospective Pilot Study of Second Primary Tumor Prevention With Erlotinib and Celecoxib in Early-Stage Squamous Cell Carcinoma of the Head and Neck: Long-Term Follow-Up. Head Neck. 2025;47:2594\u2013602.","journal-title":"Head Neck"},{"key":"612_CR106","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/archotol.133.1.28","volume":"133","author":"MB Gillespie","year":"2007","unstructured":"Gillespie MB, Moody MW, Lee FS, Poole LJ, Hornig JD, Lathers D, et al. Head and neck cancer recurrence and mortality in nonselective cyclooxygenase inhibitor users. Arch Otolaryngol Head Neck Surg. 2007;133:28\u201331.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"612_CR107","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/archotol.127.10.1253","volume":"127","author":"EC Jaeckel","year":"2001","unstructured":"Jaeckel EC, Raja S, Tan J, Das SK, Dey SK, Girod DA, et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2001;127:1253\u20139.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"612_CR108","first-page":"147","volume":"56","author":"E Escobar","year":"2023","unstructured":"Escobar E, G\u00f3mez-Valenzuela F, Pe\u00f1afiel C, Hormaz\u00e1bal-Hevia A, Herrera-Fuentes C, Mori-Aliaga D. Immunohistochemical expression of COX-2, Ki-67, Bcl-2, Bax, VEGF and CD105 according to histological grading in oral squamous cell carcinoma. Rev Esp Patol. 2023;56:147\u201357.","journal-title":"Rev Esp Patol"},{"key":"612_CR109","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.neo.7900127","volume":"3","author":"O Gallo","year":"2001","unstructured":"Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia. 2001;3:53\u201361.","journal-title":"Neoplasia"},{"key":"612_CR110","doi-asserted-by":"crossref","unstructured":"Szatmari T, Mocan S, Neagos CM, Pap Z. Biomarker Profiles and Clinicopathological Features in Head and Neck Squamous Cell Carcinoma Patients. Med (Kaunas). 2024;60.","DOI":"10.3390\/medicina60101681"},{"key":"612_CR111","doi-asserted-by":"crossref","unstructured":"Frejborg E, Salo T, Salem A. Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis. Int J Mol Sci. 2020 ;21.","DOI":"10.3390\/ijms21239246"},{"key":"612_CR112","first-page":"332","volume":"7","author":"NM Davies","year":"2004","unstructured":"Davies NM, Jamali F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharm Sci. 2004;7:332\u20136.","journal-title":"J Pharm Pharm Sci"},{"key":"612_CR113","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1001\/jama.286.8.954","volume":"286","author":"D Mukherjee","year":"2001","unstructured":"Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954\u20139.","journal-title":"JAMA"},{"key":"612_CR114","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/ehjcvp\/pvac015","volume":"8","author":"S Obeid","year":"2022","unstructured":"Obeid S, Libby P, Husni E, Wang Q, Wisniewski LM, Davey DA, et al. Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial. Eur Heart J Cardiovasc Pharmacother. 2022;8:611\u201321.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"612_CR115","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/14740338.2021.1965988","volume":"21","author":"MJ Domper Arnal","year":"2022","unstructured":"Domper Arnal MJ, Hijos-Mallada G, Lanas A. Gastrointestinal and cardiovascular adverse events associated with NSAIDs. Expert Opin Drug Saf. 2022;21:373\u201384.","journal-title":"Expert Opin Drug Saf"},{"key":"612_CR116","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.rdc.2022.08.006","volume":"49","author":"D Minhas","year":"2023","unstructured":"Minhas D, Nidhaan A, Husni ME. Recommendations for the Use of Nonsteroidal Anti-inflammatory Drugs and Cardiovascular Disease Risk: Decades Later, Any New Lessons Learned? Rheum Dis Clin North Am. 2023;49:179\u201391.","journal-title":"Rheum Dis Clin North Am"},{"key":"612_CR117","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769\u201379.","journal-title":"Lancet"},{"key":"612_CR118","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1053\/hupa.2002.125376","volume":"33","author":"O Gallo","year":"2002","unstructured":"Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol. 2002;33:708\u201314.","journal-title":"Hum Pathol"},{"key":"612_CR119","first-page":"1073","volume":"10","author":"SC Lim","year":"2003","unstructured":"Lim SC, Park SY, Do NY. Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma. Oncol Rep. 2003;10:1073\u20139.","journal-title":"Oncol Rep"},{"key":"612_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2021.12794","volume":"22","author":"S Saito","year":"2021","unstructured":"Saito S, Ozawa H, Imanishi Y, Sekimizu M, Watanabe Y, Ito F, et al. Cyclooxygenase\u20132 expression is associated with chemoresistance through cancer stemness property in hypopharyngeal carcinoma. Oncol Lett. 2021;22:1\u201310.","journal-title":"Oncol Lett"},{"key":"612_CR121","doi-asserted-by":"publisher","first-page":"e103653","DOI":"10.5812\/ijcm.103653","volume":"14","author":"M Aghili","year":"2021","unstructured":"Aghili M, Ghalehtaki R, Rayzan E, Farzin M, Mojahed MM, Izadi S, et al. The efficacy of celecoxib during chemoradiation in locally advanced head and neck carcinoma; a phase 2 randomized placebo-controlled clinical trial. Int J Cancer Manag. 2021;14:e103653.","journal-title":"Int J Cancer Manag"},{"key":"612_CR122","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1002\/hed.28178","volume":"47","author":"P Kim","year":"2025","unstructured":"Kim P, Saba NF, McCook-Veal A, Liu Y, Klein AM, Beitler JJ, et al. Prospective Pilot Study of Second Primary Tumor Prevention With Erlotinib and Celecoxib in Early\u2010Stage Squamous Cell Carcinoma of the Head and Neck: Long\u2010Term Follow\u2010Up. Head Neck. 2025;47:2594\u2013602.","journal-title":"Head Neck"},{"key":"612_CR123","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1158\/1940-6207.CAPR-13-0215","volume":"7","author":"NF Saba","year":"2014","unstructured":"Saba NF, Hurwitz SJ, Kono SA, Yang CS, Zhao Y, Chen Z, et al. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res. 2014;7:283\u201391.","journal-title":"Cancer Prev Res"},{"key":"612_CR124","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1186\/s12885-021-08903-4","volume":"21","author":"E McIlvanna","year":"2021","unstructured":"McIlvanna E, Linden GJ, Craig SG, Lundy FT, James JA. Fusobacterium nucleatum and oral cancer: a critical review. BMC Cancer. 2021;21:1212.","journal-title":"BMC Cancer"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00612-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00612-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00612-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:04:39Z","timestamp":1782727479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00612-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":124,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["612"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00612-2","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}